Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO International Convention in Boston on June 7, 2023. 12:15pm, Session Room 104A.
Breakpoint’s Managing Director and Head of Research Jon Hollick will give a talk entitled “Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold” at the DDR Inhibitors Summit in Boston, 24-26 January 2023.
Biotechnology Value Fund (BVF Partners), a San Francisco-based private investment partnership, has contributed capital in an extension of Breakpoint Therapeutics’ last funding round. Gorjan Hrustanovic, Managing Director at BVF Partners, will join Breakpoint’s Advisory Board as an Observer.
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
Breakpoint Therapeutics GmbH
Essener Bogen 7
22419 Hamburg (Germany)
Telefon: +49 40 56081 180
Registernummer: HRB 155717
Umsatzsteuer-Identifikationsnummer: DE 324 797 830
Geschäftsführer / Managing Directors
Dr. Daniel Speidel and Jonathan Hollick